Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Agenus Inc. - Common Stock (NQ:AGEN)

4.260 -0.070 (-1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Agenus, Inc.
Via Business Wire
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
From Agenus Inc.
Via Business Wire
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
From Agenus Inc.
Via Business Wire
Examining the Future: Agenus's Earnings Outlook
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Agenus's Earnings: A Preview
 
Via Benzinga
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Agenus Posts 48% Q2 Revenue Miss
Via The Motley Fool
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
From Agenus Inc.
Via Business Wire
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
From Agenus Inc.
Via Business Wire
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
From Agenus Inc.
Via Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing. 
Via Benzinga
Agenus Stock Is Trading Higher Tuesday: What's Going On?
Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab. 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
From Agenus Inc.
Via Business Wire
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Agenus Reports Q1 2025 Financial Results and Key Business Updates
From Agenus Inc.
Via Business Wire
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
From Agenus Inc.
Via Business Wire
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.